


## PHARMACEUTICAL 2022



## uniQure N.V. Rank 5 of 475

# uniQure





#### PHARMACEUTICAL 2022



# uniQure N.V. Rank 5 of 475



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 604% points. The greatest weakness of uniQure N.V. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 375%, being 651% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	628,239
Cost of Goods Sold	24,976
Intangible Assets	90,319
Liabilities, Current	36,763
Liabilities, Non-Current	176,641
Other Assets	47,117
Other Compr. Net Income	-38,763
Other Expenses	11,567
Other Liabilities	0
Other Net Income	29,662
Property and Equipment	43,505
Research and Development	143,548
Revenues	536,308
Selling, General and Administrative Expense	56,290

Output Variable	Value in 1000 USD
Assets	809,180
Liabilities	213,404
Expenses	236,381
Stockholders Equity	595,776
Net Income	329,589
Comprehensive Net Income	310,208
Economic Capital Ratio	375%